Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow NXTC by emailGet an email when NXTC pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NXTC, unsubscribe in one click. Privacy
📣 What NXTC Says Is Next
second half of 2026 · “The transaction is expected to close in the second half of 2026, subject to stockholder approval and other customary closing conditions.”
Company press release, Aug 6, 2026 · SEC filing
early 2027 · “A US IND for AVR-001 is open, and initiation of the Phase 2b study by Avere is anticipated in early 2027, with an expected readout in the first half of 2028.”
Company press release, Jul 14, 2026 · SEC filing
second half of 2026 · “NextCure anticipates increasing the number of trial sites in the second half of 2026, including the activation of sites in Canada and Europe, with continued study site additions in 2027. LNCB74 (B7-H4 ADC): Ongoing enrollment in Phase 1 dose escalation LNCB74 is a novel ADC directed to B7-H4, overexpressed in several cancers, with limited expression in healthy tissues.”
Company press release, May 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full NXTC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NXTC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.